Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Gyre Therapeutics (GYRE) Asset Utilization Ratio: 2009-2025

Historic Asset Utilization Ratio for Gyre Therapeutics (GYRE) over the last 14 years, with Sep 2025 value amounting to 0.69.

  • Gyre Therapeutics' Asset Utilization Ratio fell 19.43% to 0.69 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.69, marking a year-over-year decrease of 19.43%. This contributed to the annual value of 0.87 for FY2024, which is 22.44% down from last year.
  • Per Gyre Therapeutics' latest filing, its Asset Utilization Ratio stood at 0.69 for Q3 2025, which was down 4.99% from 0.72 recorded in Q2 2025.
  • Gyre Therapeutics' 5-year Asset Utilization Ratio high stood at 16.80 for Q3 2023, and its period low was 0.05 during Q2 2021.
  • For the 3-year period, Gyre Therapeutics' Asset Utilization Ratio averaged around 3.36, with its median value being 0.92 (2024).
  • In the last 5 years, Gyre Therapeutics' Asset Utilization Ratio soared by 1,703.18% in 2023 and then crashed by 94.92% in 2024.
  • Quarterly analysis of 5 years shows Gyre Therapeutics' Asset Utilization Ratio stood at 0.11 in 2021, then surged by 1,590.71% to 1.85 in 2022, then dropped by 2.99% to 1.79 in 2023, then slumped by 52.95% to 0.84 in 2024, then declined by 19.43% to 0.69 in 2025.
  • Its Asset Utilization Ratio was 0.69 in Q3 2025, compared to 0.72 in Q2 2025 and 0.79 in Q1 2025.